DK1262546T3 - Hidtil ukendte scavenger-receptorer - Google Patents

Hidtil ukendte scavenger-receptorer

Info

Publication number: DK1262546T3
Authority: DK; Denmark
Prior art keywords: same; scavenger receptors; proteins; lipoproteinemia; elucidation
Prior art date: 2000-02-14

Application number

DK01902805T

Other languages

English (en)

Inventor

Nobutaka Wakamiya

Original Assignee

Fuso Pharmaceutical Ind

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-14

Filing date

2001-02-08

Publication date

2010-01-04

2001-02-08 Application filed by Fuso Pharmaceutical Ind filed Critical Fuso Pharmaceutical Ind

2010-01-04 Application granted granted Critical

2010-01-04 Publication of DK1262546T3 publication Critical patent/DK1262546T3/da

Links

102000014452 scavenger receptors Human genes 0.000 title abstract 3
108010078070 scavenger receptors Proteins 0.000 title abstract 3
102000004169 proteins and genes Human genes 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
230000007246 mechanism Effects 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
208000035143 Bacterial infection Diseases 0.000 abstract 1
208000002249 Diabetes Complications Diseases 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 abstract 1
206010021024 Hypolipidaemia Diseases 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
230000002491 angiogenic effect Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
208000022362 bacterial infectious disease Diseases 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
201000001386 familial hypercholesterolemia Diseases 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
208000029498 hypoalphalipoproteinemia Diseases 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
210000002540 macrophage Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Obesity (AREA)
Neurology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)

DK01902805T 2000-02-14 2001-02-08 Hidtil ukendte scavenger-receptorer DK1262546T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2000035155		2000-02-14
JP2000309068		2000-10-10
PCT/JP2001/000874 WO2001059107A1 (fr)	2000-02-14	2001-02-08	Nouveaux recepteurs destructeurs

Publications (1)

Publication Number	Publication Date
DK1262546T3 true DK1262546T3 (da)	2010-01-04

Family

ID=26585296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01902805T DK1262546T3 (da)	2000-02-14	2001-02-08	Hidtil ukendte scavenger-receptorer

Country Status (12)

Country	Link
US (5)	US7189809B2 (da)
EP (1)	EP1262546B1 (da)
JP (1)	JP4685315B2 (da)
KR (1)	KR100514521B1 (da)
CN (1)	CN100485035C (da)
AT (1)	ATE441665T1 (da)
AU (2)	AU2001230594B2 (da)
CA (1)	CA2399865C (da)
DE (1)	DE60139765D1 (da)
DK (1)	DK1262546T3 (da)
ES (1)	ES2331107T3 (da)
WO (1)	WO2001059107A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100485035C (zh) *	2000-02-14	2009-05-06	扶桑药品工业株式会社	新型清除蛋白受体
WO2006093932A2 (en) *	2005-03-01	2006-09-08	Cedars-Sinai Medical Center	Use of eotaxin as a diagnostic indicator for atherosclerosis and vascular inflammation
JPWO2007139120A1 (ja) *	2006-05-30	2009-10-08	国立大学法人大阪大学	アミロイドβクリアランス促進剤
KR20120135405A (ko) *	2010-03-04	2012-12-13	후소 야쿠힝 고교 가부시끼가이샤	허혈성 질환 항진 작용을 갖는 폴리펩티드
CN110226567A (zh) *	2019-06-19	2019-09-13	北京林业大学	一种利用黑腹果蝇评价邻苯二甲酸酯类增塑剂的生殖毒性的方法
CN113430985A (zh) *	2021-07-02	2021-09-24	广西壮族自治区自然资源生态修复中心	乡村河道多层式生态保护修复方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK570485D0 (da) *	1985-12-10	1985-12-10	Novo Industri As	Humant conglutinin
US5270199A (en) *	1987-08-20	1993-12-14	The Children's Medical Center Corporation	Human mannose-binding protein
WO1989001519A1 (en)	1987-08-20	1989-02-23	Children's Hospital Corporation	Human mannose binding protein
JPH079124B2 (ja)	1988-07-28	1995-02-01	株式会社城南製作所	駆動装置
JP2504581B2 (ja)	1989-09-08	1996-06-05	富士通株式会社	ディジタル信号伝送方式
EP0856580A4 (en)	1995-08-17	2001-02-07	Fuso Pharmaceutical Ind	RECOMBINANT CONGLUTININ AND METHOD FOR THE PRODUCTION THEREOF
JPH09238683A (ja)	1996-03-12	1997-09-16	Eijiin Kenkyusho:Kk	ウェルナー症候群の原因遺伝子の存在する領域にある新規ｗｓ−３遺伝子及びその遺伝子がコードするタンパク質
JP3233057B2 (ja)	1997-02-27	2001-11-26	日本鋼管株式会社	溶融めっき鋼板のスパングルサイズの測定方法
WO1998055614A2 (en) *	1997-06-04	1998-12-10	Genetics Institute, Inc.	Secreted proteins and polynucleotides encoding them
JP3878737B2 (ja)	1998-01-23	2007-02-07	扶桑薬品工業株式会社	新規コレクチン
PT1108786E (pt) *	1998-08-24	2007-02-28	Fuso Pharmaceutical Ind	Nova colectina
CA2372815A1 (en)	1999-05-11	2000-11-16	Incyte Genomics, Inc.	Extracellular matrix and adhesion-associated proteins
CN100485035C (zh) *	2000-02-14	2009-05-06	扶桑药品工业株式会社	新型清除蛋白受体
AU2001248840B2 (en)	2000-04-21	2005-06-09	Fuso Pharmaceutical Industries, Ltd.	Novel collectins

2001
- 2001-02-08 CN CNB018081363A patent/CN100485035C/zh not_active Expired - Fee Related
- 2001-02-08 KR KR10-2002-7010588A patent/KR100514521B1/ko not_active IP Right Cessation
- 2001-02-08 AU AU2001230594A patent/AU2001230594B2/en not_active Ceased
- 2001-02-08 DK DK01902805T patent/DK1262546T3/da active
- 2001-02-08 CA CA2399865A patent/CA2399865C/en not_active Expired - Fee Related
- 2001-02-08 AT AT01902805T patent/ATE441665T1/de not_active IP Right Cessation
- 2001-02-08 EP EP01902805A patent/EP1262546B1/en not_active Expired - Lifetime
- 2001-02-08 JP JP2001558245A patent/JP4685315B2/ja not_active Expired - Fee Related
- 2001-02-08 ES ES01902805T patent/ES2331107T3/es not_active Expired - Lifetime
- 2001-02-08 WO PCT/JP2001/000874 patent/WO2001059107A1/ja not_active Application Discontinuation
- 2001-02-08 DE DE60139765T patent/DE60139765D1/de not_active Expired - Lifetime
- 2001-02-08 AU AU3059401A patent/AU3059401A/xx active Pending
- 2001-02-08 US US10/203,860 patent/US7189809B2/en not_active Expired - Fee Related
2007
- 2007-03-12 US US11/716,967 patent/US7612175B2/en not_active Expired - Fee Related
- 2007-03-12 US US11/716,893 patent/US7612174B2/en not_active Expired - Fee Related
2009
- 2009-10-15 US US12/579,948 patent/US8084578B2/en not_active Expired - Fee Related
- 2009-10-15 US US12/579,968 patent/US8410253B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1646689A (zh)	2005-07-27
US8410253B2 (en)	2013-04-02
KR20020089351A (ko)	2002-11-29
US20100113750A1 (en)	2010-05-06
CN100485035C (zh)	2009-05-06
US20070224649A1 (en)	2007-09-27
AU3059401A (en)	2001-08-20
WO2001059107A1 (fr)	2001-08-16
US20100113749A1 (en)	2010-05-06
ES2331107T3 (es)	2009-12-22
US7612174B2 (en)	2009-11-03
US7189809B2 (en)	2007-03-13
US8084578B2 (en)	2011-12-27
CA2399865A1 (en)	2001-08-16
US7612175B2 (en)	2009-11-03
ATE441665T1 (de)	2009-09-15
EP1262546B1 (en)	2009-09-02
DE60139765D1 (de)	2009-10-15
KR100514521B1 (ko)	2005-09-14
AU2001230594B2 (en)	2004-11-11
JP4685315B2 (ja)	2011-05-18
CA2399865C (en)	2011-10-25
US20030108904A1 (en)	2003-06-12
EP1262546A1 (en)	2002-12-04
US20070231859A1 (en)	2007-10-04
EP1262546A4 (en)	2004-07-14

Similar Documents

Publication	Publication Date	Title
ATE376559T1 (de)	2007-11-15	Methoden der verhinderung und behandlung der alzheimer'schen krankheit
EP1731166A3 (en)	2007-02-21	Streptococcus pneumoniae proteins and vaccines
AU2003270643A1 (en)	2004-04-30	Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
UA87093C2 (ru)	2009-06-25	ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
PT1200105E (pt)	2005-06-30	Factor viii modificado
PL392964A1 (pl)	2011-01-03	Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania
DK1368060T3 (da)	2010-08-30	HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EA200101250A1 (ru)	2002-06-27	Предупреждение и терапия амилоидогенного заболевания
BR0109650A (pt)	2003-04-22	3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
EA200300293A1 (ru)	2003-08-28	Противовоспалительные конденсированные пирролокарбазолы
BRPI0410684A (pt)	2006-06-20	uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
AU2002223640A1 (en)	2002-05-06	Fusion proteins as immunization treatments of alzheimer's disease
DK1265928T3 (da)	2010-11-15	RSV-neutraliserende antistoffer med ultra høj affinitet
CN101107264A (zh)	2008-01-16	C5a受体拮抗剂
WO2005030258A3 (en)	2005-09-22	Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2003039225A3 (en)	2004-03-04	Antigen arrays comprising rankl for treatment of bone disease
DK1262546T3 (da)	2010-01-04	Hidtil ukendte scavenger-receptorer
CY1110401T1 (el)	2015-04-29	Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
WO2002057796A3 (en)	2003-03-27	Compounds for treating pathologies associated with molecular crystallization
Johannesson et al.	1999	Angiotensin II analogues encompassing 5, 9-and 5, 10-fused thiazabicycloalkane tripeptide mimetics
WO2002003922A2 (en)	2002-01-17	Synthetic peptide for neurological disorders
ATE393170T1 (de)	2008-05-15	Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
ATE401402T1 (de)	2008-08-15	Mit syndekan interagierende proteine und deren verwendung
Lozano et al.	2013	Redefining an epitope of a malaria vaccine candidate, with antibodies against the N-terminal MSA-2 antigen of Plasmodium harboring non-natural peptide bonds
ATE397753T1 (de)	2008-06-15	Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung